Keywords: Actelion, Ponesimod, Psoriasis

Actelion's ponesimod does well in mid-stage psoriasis trial

Article | 18 December 2012

Print This

Europe’s largest biotech firm Actelion (SIX: ATLN) says that its selective S1P1 modulator, ponesimod, successfully met the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in